Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer

A. E. Ross, A. V. D'Amico, S. J. Freedland

Research output: Contribution to journalArticle

Abstract

An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe which is best supported for use in various clinical scenarios. Literature regarding testing of human prostate cancer tissue with Ki-67, PTEN (by immunohistochemistry (IHC) or fluroescence in situ hybridization (FISH)), ProMark, Prolaris, OncotypeDX Prostate and Decipher was reviewed to allow for generation of expert opinions. At diagnosis, evaluation of PTEN status, use of ProMark or OncotypeDX Prostate in men with Gleason 6 or 3+4=7 disease may help guide the use of active surveillance. For men with Gleason 7 or above disease considering watchful waiting, Ki-67 and Prolaris add independent prognostic information. For those men who have undergone prostatectomy and have adverse pathology, Decipher testing may aid in the decision to undergo adjuvant radiation. Newly available molecular tests bring opportunities to improve decision making for men with localized prostate cancer. A review of the currently available data suggests clinical scenarios for which each of these tests may have the greatest utility.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume19
Issue number1
DOIs
StatePublished - Mar 1 2016

Fingerprint

Prostatic Neoplasms
Prostate
Watchful Waiting
Aptitude
Decision Support Techniques
Expert Testimony
Prostatectomy
In Situ Hybridization
Molecular Biology
Decision Making
Immunohistochemistry
Radiation
Pathology

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. / Ross, A. E.; D'Amico, A. V.; Freedland, S. J.

In: Prostate Cancer and Prostatic Diseases, Vol. 19, No. 1, 01.03.2016, p. 1-6.

Research output: Contribution to journalArticle

@article{d32918e204554c2287954642c783f106,
title = "Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer",
abstract = "An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe which is best supported for use in various clinical scenarios. Literature regarding testing of human prostate cancer tissue with Ki-67, PTEN (by immunohistochemistry (IHC) or fluroescence in situ hybridization (FISH)), ProMark, Prolaris, OncotypeDX Prostate and Decipher was reviewed to allow for generation of expert opinions. At diagnosis, evaluation of PTEN status, use of ProMark or OncotypeDX Prostate in men with Gleason 6 or 3+4=7 disease may help guide the use of active surveillance. For men with Gleason 7 or above disease considering watchful waiting, Ki-67 and Prolaris add independent prognostic information. For those men who have undergone prostatectomy and have adverse pathology, Decipher testing may aid in the decision to undergo adjuvant radiation. Newly available molecular tests bring opportunities to improve decision making for men with localized prostate cancer. A review of the currently available data suggests clinical scenarios for which each of these tests may have the greatest utility.",
author = "Ross, {A. E.} and D'Amico, {A. V.} and Freedland, {S. J.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/pcan.2015.31",
language = "English (US)",
volume = "19",
pages = "1--6",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer

AU - Ross, A. E.

AU - D'Amico, A. V.

AU - Freedland, S. J.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe which is best supported for use in various clinical scenarios. Literature regarding testing of human prostate cancer tissue with Ki-67, PTEN (by immunohistochemistry (IHC) or fluroescence in situ hybridization (FISH)), ProMark, Prolaris, OncotypeDX Prostate and Decipher was reviewed to allow for generation of expert opinions. At diagnosis, evaluation of PTEN status, use of ProMark or OncotypeDX Prostate in men with Gleason 6 or 3+4=7 disease may help guide the use of active surveillance. For men with Gleason 7 or above disease considering watchful waiting, Ki-67 and Prolaris add independent prognostic information. For those men who have undergone prostatectomy and have adverse pathology, Decipher testing may aid in the decision to undergo adjuvant radiation. Newly available molecular tests bring opportunities to improve decision making for men with localized prostate cancer. A review of the currently available data suggests clinical scenarios for which each of these tests may have the greatest utility.

AB - An increased molecular understanding of localized prostate cancer and the improved ability for molecular testing of pathologic tissue has led to the development of multiple clinical assays. Here we review the relevant molecular biology of localized prostate cancer, currently available tissue-based tests and describe which is best supported for use in various clinical scenarios. Literature regarding testing of human prostate cancer tissue with Ki-67, PTEN (by immunohistochemistry (IHC) or fluroescence in situ hybridization (FISH)), ProMark, Prolaris, OncotypeDX Prostate and Decipher was reviewed to allow for generation of expert opinions. At diagnosis, evaluation of PTEN status, use of ProMark or OncotypeDX Prostate in men with Gleason 6 or 3+4=7 disease may help guide the use of active surveillance. For men with Gleason 7 or above disease considering watchful waiting, Ki-67 and Prolaris add independent prognostic information. For those men who have undergone prostatectomy and have adverse pathology, Decipher testing may aid in the decision to undergo adjuvant radiation. Newly available molecular tests bring opportunities to improve decision making for men with localized prostate cancer. A review of the currently available data suggests clinical scenarios for which each of these tests may have the greatest utility.

UR - http://www.scopus.com/inward/record.url?scp=84957840165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957840165&partnerID=8YFLogxK

U2 - 10.1038/pcan.2015.31

DO - 10.1038/pcan.2015.31

M3 - Article

C2 - 26123120

AN - SCOPUS:84957840165

VL - 19

SP - 1

EP - 6

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 1

ER -